Let’s dive into:

- Rising opportunities driven by the growing market for veterinary

biological drugs and social trends

- First-of-a-kind donor-based cell therapy that’s shaping the future of pet medicine

- Successful clinical trials results for osteoarthritis in dogs, atopic dermatitis in dogs, osteoarthritis in horses

Creating scale in nutritional health requires more than just a pipeline of products, it demands smart capital and commercial innovation. Bill Weldon shares how Axiota has successfully leveraged private equity backing to merge platforms, secure FDA approval, expand geographically, and ultimately scale into a profitable business.

Grant funding can be a catalyst for scientific and commercial progress. Adriann Sax, CEO & Co-Founder of Vetigenics, shares how strategic use of SBIR and foundation grants enabled the company to build a canine antibody platform, attract support from investors, and secure partners such as Merck Animal Health.

Breaking into the animal health vaccines market requires overcoming high regulatory barriers and providing speed in response to outbreaks and evolving variants. Hanjo Hennemann shares how VEROVACCiNES leveraged a recombinant platform to rapidly design, test, and scale vaccines utilising regulatory pathways for broader and faster market entry.